Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Denali Therapeutics Inc.

NAS: DNLI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Denali Therapeutics Inc.

After Hours

 --Real time quotes

Dec 2, 2021, 5:55 p.m.

DNLI
/zigman2/quotes/200043077/composite

$

44.51

Change

0.00 0.00%

Volume

Volume 32,982

Real time quotes

/zigman2/quotes/200043077/composite

Previous close

$ 44.42

$ 44.51

Change

+0.09 +0.20%

Day low

Day high

$43.09

$44.76

Open

52 week low

52 week high

$43.09

$93.94

Open

Company Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lav...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Valuation

P/E Current

70.38

P/E Ratio (with extraordinary items)

182.91

P/E Ratio (without extraordinary items)

132.70

Price to Sales Ratio

28.12

Price to Book Ratio

8.77

Price to Cash Flow Ratio

79.51

Enterprise Value to EBITDA

58.41

Enterprise Value to Sales

11.40

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

1,153,467.00

Income Per Employee

244,454.00

Total Asset Turnover

0.31

Liquidity

Current Ratio

20.86

Quick Ratio

20.86

Cash Ratio

20.50

Profitability

Operating Margin

18.69

Pretax Margin

21.44

Net Margin

21.19

Return on Assets

6.59

Return on Equity

9.21

Return on Total Capital

7.44

Return on Invested Capital

8.48

Capital Structure

Total Debt to Total Equity

5.99

Total Debt to Total Capital

5.65

Total Debt to Total Assets

4.29

Long-Term Debt to Equity

5.58

Long-Term Debt to Total Capital

5.26

Officers and Executives

Name Age Officer Since Title
Dr. Ryan J. Watts 43 2013 President, Director & Chief Scientific Officer
Dr. Alexander O. Schuth 45 2013 Chief Operating Officer
Mr. Steve E. Krognes 51 2015 Chief Financial Officer
Dr. Joe Lewcock - 2020 Chief Scientific Officer
Dr. Carole Ho 47 2015 Chief Medical Officer & Head-Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/10/2021 Vicki L. Sato
Director 		660   Disposition at $53.3 per share. 35,178
11/10/2021 Vicki L. Sato
Director 		1,006   Disposition at $52.49 per share. 52,804
11/04/2021 Alexander O. Schuth
COO and Secretary 		3,283   Disposition at $53.23 per share. 174,754
11/04/2021 Alexander O. Schuth
COO and Secretary 		6,717   Disposition at $52.65 per share. 353,650
11/01/2021 Ryan J. Watts
President and CEO; Director 		16,674   Disposition at $49.87 per share. 831,532
11/01/2021 Ryan J. Watts
President and CEO; Director 		1,659   Disposition at $48.61 per share. 80,643
11/01/2021 Vicki L. Sato
Director 		1,666   Disposition at $50.05 per share. 83,383
10/04/2021 Alexander O. Schuth
COO and Secretary 		4,006   Disposition at $51.04 per share. 204,466
10/04/2021 Alexander O. Schuth
COO and Secretary 		5,994   Disposition at $50.24 per share. 301,138
10/01/2021 Ryan J. Watts
President and CEO; Director 		4,247   Disposition at $50.99 per share. 216,554
10/01/2021 Ryan J. Watts
President and CEO; Director 		10,782   Disposition at $50.44 per share. 543,844
10/01/2021 Ryan J. Watts
President and CEO; Director 		3,304   Disposition at $49.38 per share. 163,151
09/20/2021 Alexander O. Schuth
COO and Secretary 		9,045   Derivative/Non-derivative trans. at $0.68 per share. 6,150
09/15/2021 Vicki L. Sato
Director 		140   Disposition at $54.76 per share. 7,666
09/15/2021 Vicki L. Sato
Director 		620   Disposition at $53.92 per share. 33,430
09/15/2021 Vicki L. Sato
Director 		676   Disposition at $53.03 per share. 35,848
09/15/2021 Vicki L. Sato
Director 		230   Disposition at $52.28 per share. 12,024
09/01/2021 Ryan J. Watts
President and CEO; Director 		10,892   Disposition at $54.92 per share. 598,188
09/01/2021 Ryan J. Watts
President and CEO; Director 		7,441   Disposition at $54.27 per share. 403,823
08/23/2021 Carole Ho
Chief Medical Officer 		6,143   Disposition at $48.91 per share. 300,454
08/19/2021 Ryan J. Watts
President and CEO; Director 		750   Disposition at $49.97 per share. 37,477
08/19/2021 Ryan J. Watts
President and CEO; Director 		1,626   Disposition at $49.38 per share. 80,291
08/19/2021 Steve E. Krognes
CFO and Treasurer 		200   Disposition at $50.07 per share. 10,014
08/19/2021 Steve E. Krognes
CFO and Treasurer 		2,085   Disposition at $49.52 per share. 103,249
08/19/2021 Alexander O. Schuth
COO and Secretary 		196   Disposition at $50.1 per share. 9,819
08/19/2021 Alexander O. Schuth
COO and Secretary 		2,348   Disposition at $49.56 per share. 116,366
08/19/2021 Carole Ho
Chief Medical Officer 		1,144   Disposition at $49.91 per share. 57,097
08/19/2021 Carole Ho
Chief Medical Officer 		1,402   Disposition at $49.31 per share. 69,132
/news/latest/company/us/dnli

MarketWatch News on DNLI

  1. 4 Beaten-Down Biotech Stocks That Could Take Off

    3:07 p.m. Nov. 17, 2021

    - Barron's Online

  2. Denali Therapeutics started at outperform with $85 stock price target at Oppenheimer

    6:16 a.m. Sept. 21, 2021

    - Tomi Kilgore

  3. Biogen's Alzheimer's Drug Is Approved by the FDA

    1:02 p.m. June 7, 2021

    - Barron's Online

  5. Don’t Expect Amazon Prime Day to Move the Stock

    7:26 a.m. June 2, 2021

    - Barron's Online

  6. The FDA's Biogen Decision Will Cause Waves Across Biotech

    8:20 p.m. June 1, 2021

    - Barron's Online

  7. Denali Therapeutics started at buy with $70 stock price target at UBS

    8:03 a.m. May 18, 2021

    - Tomi Kilgore

  8. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  9. The 12 Most Overpriced Stocks in America

    7:48 a.m. Dec. 28, 2020

    - Barron's Online

  11. Denali down 10% on pause in neurological drug

    4:53 p.m. June 9, 2020

    - MarketWatch.com

  12. Panic Takes Hold

    7:39 p.m. March 12, 2020

    - Barron's Online

  13. Denali Therapeutics upgraded to outperform from neutral at Wedbush

    8:05 a.m. Feb. 28, 2020

    - Tomi Kilgore

  14. Denali Therapeutics started at hold with $26 stock price target at Stifel Nicolaus

    7:40 a.m. Feb. 19, 2020

    - Tomi Kilgore

  15. Denali Therapeutics started at neutral with $19 stock price target at Wedbush

    7:22 a.m. Sept. 26, 2019

    - Tomi Kilgore

  16. Denali Therapeutics started at buy with $35 stock price target at Instinet

    7:35 a.m. Sept. 13, 2019

    - Tomi Kilgore

  17. Jeffrey Epstein’s Investing Lagged Behind the Market

    12:23 p.m. July 17, 2019

    - Barron's Online

  19. Harry Boxer’s 4 stocks running on earnings

    1:42 p.m. March 14, 2019

    - Harry Boxer

  20. Denali Therapeutics started at market perform at Raymond James

    7:57 a.m. Nov. 30, 2018

    - Tomi Kilgore

  21. Loading more headlines...
/news/nonmarketwatch/company/us/dnli

Other News on DNLI

  9. 10-Q: DENALI THERAPEUTICS INC.

    4:13 p.m. Nov. 4, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  12. Ron Baron Comments on Denali Therapeutics

    3:07 p.m. Oct. 26, 2021

    - GuruFocus.com

  13. Ron Baron's Baron Growth Fund 3rd-Quarter Letter

    2:49 p.m. Oct. 26, 2021

    - GuruFocus.com

  14. Warning: DNLI is at high risk of performing badly

    4:39 a.m. Oct. 21, 2021

    - Seeking Alpha

  16. New Strong Sell Stocks for October 12th

    11:00 a.m. Oct. 12, 2021

    - Zacks.com

  20. Denali/Sanofi ALS candidate granted FDA Fast Track status

    4:18 p.m. Oct. 6, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Denali Therapeutics, Inc.

161 Oyster Point Boulevard

San Francisco, California 94080

Phone

1 6158668548

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$335.66M

Net Income

$71.14M

2020 Sales Growth

1158.2%

Employees

291.00

Annual Report for DNLI

/news/pressrelease/company/us/dnli

Press Releases on DNLI

  11. FRP Tank Market to Witness Growth Acceleration During 2020-2025

    11:59 a.m. Aug. 31, 2021

    - Market Insight Reports

  13. FRP Tank Market to Experience Rebound in Sales post COVID-19

    6:09 a.m. Aug. 19, 2021

    - Market Insight Reports

  21. Loading more headlines...
Link to MarketWatch's Slice.